{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:53:11Z","timestamp":1780631591362,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":4885,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1093\/annonc\/mdl135","type":"journal-article","created":{"date-parts":[[2006,6,10]],"date-time":"2006-06-10T00:39:26Z","timestamp":1149899966000},"page":"1205-1212","source":"Crossref","is-referenced-by-count":166,"title":["Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen"],"prefix":"10.1016","volume":"17","author":[{"given":"M.","family":"Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Adrover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Rodr\u00edguez-Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fernandez-Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Mart\u00ednez","family":"del Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zaluski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arcusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"L\u00f3pez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Mel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl135_bb0010","first-page":"30","article-title":"Polychemotherapy for early breast cancer: an overview of the randomised trials","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl135_bb0015","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdl135_bb0020","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","article-title":"Adjuvant docetaxel for node-positive breast cancer","volume":"352","author":"Martin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl135_bb0025","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMe058056","article-title":"TAC\u2014A new standard in adjuvant therapy for breast cancer?","volume":"352","author":"Perez","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl135_bb0030","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jnci\/90.21.1601","article-title":"Meeting highlights: International consensus panel on the treatment of primary breast cancer","volume":"90","author":"Goldhirsch","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl135_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Tretament of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl135_bb0040","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1200\/JCO.1996.14.10.2756","article-title":"The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study","volume":"14","author":"Sprangers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl135_bb0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jnci\/95.4.263","article-title":"Health-related quality-of-life measurement in randomized clinical trials in breast cancer\u2014taking stock","volume":"5","author":"Goodwin","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl135_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl135_bb0055","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors Evidence-based clinical practice guidelines\u2014American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl135_bb0060","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0959-8049(98)00222-6","article-title":"The economics of febrile neutropenia: Implications for the use of colony-stimulating factors","volume":"34","author":"Lyman","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdl135_bb0065","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pelfisgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl135_bb0070","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.293.19.2367","article-title":"Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer","volume":"293","author":"Brain","year":"2005","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdl135_bb0075","series-title":"Approach to the adult and child with anemia","first-page":"367","article-title":"Hematology. Basic Principles and Practice","author":"Schnall","year":"2000"},{"key":"10.1093\/annonc\/mdl135_bb0080","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","article-title":"Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of urothelium","volume":"318","author":"Gabrilove","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl135_bb0085","series-title":"Puri RJ (eds). Human Cytokines: Their Role in Disease and Therapy","author":"Aggarwal","year":"1995"},{"key":"10.1093\/annonc\/mdl135_bb0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdf122","article-title":"The impact of hemoglobin levels on fatigue and quality of life in cancer patients","volume":"3","author":"Holzner","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl135_bb0095","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bjc.6600247","article-title":"The level of hemoglobin in anaemic cancer patients correlates positively with quality of life","volume":"86","author":"Lind","year":"2002","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdl135_bb0100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1359-6349(06)80376-9","article-title":"Pegfilgastrim alone or with ciproflaxin significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadjuvant chemotherapy with docetaxel\/doxorubicin\/cyclophosphamide (TAC)","volume":"4","author":"von Minckwitz","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdl135_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0037-1963(00)90060-X","article-title":"Overview: Erythropoiesis, anemia and the impact of erythropoietin","volume":"37","author":"Gabrilove","year":"2000","journal-title":"Sem Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419476242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/8\/1205\/418085\/mdl135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:54:08Z","timestamp":1582217648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419476242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0923753419476242"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl135","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}